Quantcast

Latest AVI BioPharma Stories

974d63c1037b0b191ef80ca7939788131
2010-08-23 06:20:00

Ebola may soon be easier to fight thanks to a new treatment being tested by US scientists. A treatment administered to rhesus monkeys within an hour of being incepted by the deadliest strain of Ebola was 60 percent effective, and a companion drug was 100-percent effective. The U.S. Food and Drug Administration (FDA) said they have given the green light for trials on a small group of human volunteers. The Ebola virus is part of a family of so-called filoviruses, which cause hemorrhagic fever...

2009-10-20 09:28:53

New publication in Molecular Therapy outlines dramatic effects in animals treated with splice switching PPMO, demonstrates promise for treatment of Duchenne muscular dystrophy An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. These findings were published online today in the journal Molecular Therapy and...

2008-11-11 09:00:46

AVI BioPharma, a developer of RNA-based drugs, has announced that its partner Global Therapeutics, a Cook Medical company, has initiated a clinical trial of a drug eluting stent that uses a peptide-conjugated morpholino phosphorodiamidate oligomer-based RNA therapeutic agent aimed at silencing C-MYC, one of the genes responsible for causing arteries to reclose after stenting. The feasibility study is a prospective, open-label, multi-center trial being performed in Germany. As many as 90...

2008-10-15 09:00:47

AVI BioPharma has announced that the European Medicines Agency Committee for Orphan Medicinal Products adopted a positive opinion recommending orphan medicinal product designation for AVI-4658 to treat Duchenne muscular dystrophy. The company believes the positive opinion of the Committee for Orphan Medicinal Products (COMP) will serve as the scientific basis for the European Commission to issue a EU orphan designation pursuant to Regulation (ED) 141/2000. Additionally, AVI BioPharma...

2008-10-14 12:00:32

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the Company -- along with The Foundation to Eradicate Duchenne, the CureDuchenne Foundation, and Prosensa -- will co-host an exon skipping conference for Duchenne muscular dystrophy (DMD) from October 14-17, 2008 at the Banbury Center of Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Invited participants will be drawn from all over the world and from all areas of research, clinical development,...

2008-10-14 09:00:11

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the European Medicines Agency (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending orphan medicinal product designation for AVI-4658 to treat Duchenne muscular dystrophy (DMD). Additionally, the Company received notification from the Gene Therapy Advisory Committee (GTAC) in the UK granting provisional approval for the Company's planned clinical trial for systemic...

2008-10-01 12:00:31

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present at two upcoming healthcare conferences. The first is the JMP Securities Healthcare Focus Conference, to be held October 6-7, 2008 at Le Parker Meridien Hotel in New York City. Dr. Hudson's presentation is scheduled on October 6 at 4:30 p.m. Eastern time. Slides and the webcast link will be available on the Company's website at www.avibio.com...

2008-09-22 09:00:58

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present an update on the continuing transition of AVI from an antisense pioneer into a leading discoverer and developer of RNA-based drugs. The corporate overview will include an update on AVI's Duchenne muscular dystrophy program (DMD), its biodefense projects (which include significant data from the Company's ongoing Ebola and Marburg virus programs in...

2008-09-08 09:00:52

AVI BioPharma, Inc. (NASDAQ: AVII) announced today that it will host a breakfast meeting for analysts, brokers, investors and the Company's shareholders on Wednesday, September 10, 2008, from 7:30 a.m. to 10:30 a.m. EDT at the Harvard Club of New York City. AVI's senior management team will be joined by Dr. Francesco Muntoni, Professor of Pediatric Neurology, University College London Institute of Child Health, and Ben Johnson, Engineering Manager at Global Therapeutics, a Cook Medical...

2008-08-11 09:01:40

AVI BioPharma, Inc. (NASDAQ: AVII) today reported financial results for the three and six months ending June 30, 2008. The Company also reported that it has received approval from the Medicine and Healthcare Product Regulatory Agency (MHRA) to conduct its systemic trial of AVI-4658 in the treatment of Duchenne Muscular Dystrophy in the United Kingdom and also updated the new additions to its senior management team. "As we continue AVI's transformation from an antisense pioneer into an...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related